DOI QR코드

DOI QR Code

Prognostic Threshold of Neuroendocrine Differentiation in Gastric Carcinoma: a Clinicopathological Study of 945 Cases

  • Zou, Yi (Department of Pathology, The First Affiliated Hospital of Fujian Medical University) ;
  • Chen, Linying (Department of Pathology, The First Affiliated Hospital of Fujian Medical University) ;
  • Wang, Xingfu (Department of Pathology, The First Affiliated Hospital of Fujian Medical University) ;
  • Chen, Yupeng (Department of Pathology, The First Affiliated Hospital of Fujian Medical University) ;
  • Hu, Liwen (Department of Pathology, The First Affiliated Hospital of Fujian Medical University) ;
  • Zeng, Saifan (Department of Pathology, The First Affiliated Hospital of Fujian Medical University) ;
  • Wang, Pengcheng (Department of Pathology, The First Affiliated Hospital of Fujian Medical University) ;
  • Li, Guoping (Department of Pathology, The First Affiliated Hospital of Fujian Medical University) ;
  • Huang, Ming (Public Security Bureau of Changle City) ;
  • Wang, Liting (Department of Pathology, No. 2 Hospital) ;
  • He, Shi (Department of Pathology, Fujian Provincial Cancer Hospital) ;
  • Li, Sanyan (Department of Pathology, The First Affiliated Hospital of Fujian Medical University) ;
  • Jian, Lihui (Maternity and Child Care Hospital of Huli District) ;
  • Zhang, Sheng (Department of Pathology, The First Affiliated Hospital of Fujian Medical University)
  • Received : 2018.11.08
  • Accepted : 2019.03.12
  • Published : 2019.03.31

Abstract

Purpose: The significance of neuroendocrine differentiation (NED) in gastric carcinoma (GC) is controversial, leading to ambiguous concepts in traditional classifications. This study aimed to determine the prognostic threshold of meaningful NED in GC and clarify its unclear features in existing classifications. Materials and Methods: Immunohistochemical staining for synaptophysin, chromogranin A, and neural cell adhesion molecule was performed for 945 GC specimens. Survival analysis was performed using the log-rank test and univariate/multivariate models with percentages of NED ($P_{NED}$) and demographic and clinicopathological parameters. Results: In total, 275 (29.1%) cases were immunoreactive to at least 1 neuroendocrine (NE) marker. GC-NED was more common in the upper third of the stomach. $P_{NED}$, and Borrmann's classification and tumor, lymph node, metastasis stages were independent prognostic factors. The cutoff $P_{NED}$ was 10%, beyond which patients had significantly worse outcomes, although the risk did not increase with higher $P_{NED}$. Tumors with ${\geq}10%$ NED tended to manifest as Borrmann type III lesion with mixed/diffuse morphology and poorer histological differentiation; the NE components in this population mainly grew in insulae/nests, which differed from the predominant growth pattern (glandular/acinar) in GC with <10% NED. Conclusions: GC with ${\geq}10%$ NED should be classified as a distinct subtype because of its worse prognosis, and more attention should be paid to the necessity of additional therapeutics for NE components.

Keywords

References

  1. Ooi A, Mai M, Ogino T, Ueda H, Kitamura T, Takahashi Y, et al. Endocrine differentiation of gastric adenocarcinoma. The prevalence as evaluated by immunoreactive chromogranin A and its biologic significance. Cancer 1988;62:1096-1104. https://doi.org/10.1002/1097-0142(19880915)62:6<1096::AID-CNCR2820620612>3.0.CO;2-T
  2. Qvigstad G, Sandvik AK, Brenna E, Aase S, Waldum HL. Detection of chromogranin A in human gastric adenocarcinomas using a sensitive immunohistochemical technique. Histochem J 2000;32:551-556. https://doi.org/10.1023/A:1004102312006
  3. Sentani K, Oue N, Noguchi T, Sakamoto N, Matsusaki K, Yasui W. Immunostaining of gastric cancer with neuroendocrine differentiation: Reg IV-positive neuroendocrine cells are associated with gastrin, serotonin, pancreatic polypeptide and somatostatin. Pathol Int 2010;60:291-297. https://doi.org/10.1111/j.1440-1827.2010.02519.x
  4. Jiang SX, Mikami T, Umezawa A, Saegusa M, Kameya T, Okayasu I. Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity. Am J Surg Pathol 2006;30:945-953. https://doi.org/10.1097/00000478-200608000-00003
  5. Canzonieri V, Colarossi C, Del Col L, Perin T, Talamini R, Sigon R, et al. Exocrine and endocrine modulation in common gastric carcinoma. Am J Clin Pathol 2012;137:712-721. https://doi.org/10.1309/AJCPM13KVNCZQBUV
  6. Eren F, Celikel C, Gulluoglu B. Neuroendocrine differentiation in gastric adenocarcinomas; correlation with tumor stage and expression of VEGF and p53. Pathol Oncol Res 2004;10:47-51. https://doi.org/10.1007/BF02893409
  7. Blumenfeld W, Chandhoke DK, Sagerman P, Turi GK. Neuroendocrine differentiation in gastric adenocarcinomas. An immunohistochemical study. Arch Pathol Lab Med 1996.120:478-481.
  8. Waldum HL, Aase S, Kvetnoi I, Brenna E, Sandvik AK, Syversen U, et al. Neuroendocrine differentiation in human gastric carcinoma. Cancer 1998;83:435-444. https://doi.org/10.1002/(SICI)1097-0142(19980801)83:3<435::AID-CNCR11>3.0.CO;2-X
  9. Fujii A, Kamiakito T, Takayashiki N, Fujii T, Tanaka A. Neuroendocrine tissue-specific transcription factor, BETA2/NeuroD, in gastric carcinomas: a comparison with chromogranin A and synaptophysin expressions. Pathol Res Pract 2003;199:513-519. https://doi.org/10.1078/0344-0338-00456
  10. Wang LL, Yao GY, Zhao ZS, Wei XL, Xu RJ. Clonality analysis of neuroendocrine cells in gastric adenocarcinoma. World J Gastroenterol 2013;19:5340-5346. https://doi.org/10.3748/wjg.v19.i32.5340
  11. Yao GY, Zhou JL, Lai MD, Chen XQ, Chen PH. Neuroendocrine markers in adenocarcinomas: an investigation of 356 cases. World J Gastroenterol 2003;9:858-861. https://doi.org/10.3748/wjg.v9.i4.858
  12. Zhang T, Su D, Mao Z, Guo X, Wang L, Bai L. Prognostic role of neuroendocrine cell differentiation in human gastric carcinoma. Int J Clin Exp Med 2015;8:7837-7842.
  13. Kim JJ, Kim JY, Hur H, Cho YK, Han SU. Clinicopathologic significance of gastric adenocarcinoma with neuroendocrine features. J Gastric Cancer 2011;11:195-199. https://doi.org/10.5230/jgc.2011.11.4.195
  14. Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: International Agency for Research on Cancer, 2010.
  15. Park JY, Ryu MH, Park YS, Park HJ, Ryoo BY, Kim MG, et al. Prognostic significance of neuroendocrine components in gastric carcinomas. Eur J Cancer 2014;50:2802-2809. https://doi.org/10.1016/j.ejca.2014.08.004
  16. Kim TY, Chae HD. Composite neuroendocrine carcinoma with adenocarcinoma of the stomach misdiagnosed as a giant submucosal tumor. J Gastric Cancer 2011;11:126-130. https://doi.org/10.5230/jgc.2011.11.2.126
  17. Granberg D, Wilander E, Stridsberg M, Granerus G, Skogseid B, Oberg K. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut 1998;43:223-228. https://doi.org/10.1136/gut.43.2.223
  18. Volante M, Rindi G, Papotti M. The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine-endocrine neoplasms. Virchows Arch 2006;449:499-506. https://doi.org/10.1007/s00428-006-0306-2
  19. Lewin K. Carcinoid tumors and the mixed (composite) glandular-endocrine cell carcinomas. Am J Surg Pathol 1987;11 Suppl 1:71-86. https://doi.org/10.1097/00000478-198700111-00007
  20. Chang S, Choi D, Lee SJ, Lee WJ, Park MH, Kim SW, et al. Neuroendocrine neoplasms of the gastrointestinal tract: classification, pathologic basis, and imaging features. Radiographics 2007;27:1667-1679. https://doi.org/10.1148/rg.276075001
  21. Leoncini E, Carioli G, La Vecchia C, Boccia S, Rindi G. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol 2016;27:68-81. https://doi.org/10.1093/annonc/mdv505
  22. Gill S, Shah A, Le N, Cook EF, Yoshida EM. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a Canadian cancer center. J Clin Oncol 2003;21:2070-2076. https://doi.org/10.1200/JCO.2003.11.054
  23. Ng CJ, Teo CH, Abdullah N, Tan WP, Tan HM. Relationships between cancer pattern, country income and geographical region in Asia. BMC Cancer 2015;15:613. https://doi.org/10.1186/s12885-015-1615-0
  24. Tanaka T, Kaneko M, Nozawa H, Emoto S, Murono K, Otani K, et al. Diagnosis, assessment, and therapeutic strategy for colorectal mixed adenoneuroendocrine carcinoma. Neuroendocrinology 2017;105:426-434. https://doi.org/10.1159/000478743
  25. Chen H, Shu M, Chen S, Xue L, Lin Y. Clinicopathological features and lymph node metastatic patterns of gastric mixed adenoneuroendocrine carcinoma. Histol Histopathol 2018. doi: 10.14670/HH-18-045 [In press].
  26. Xie JW, Lu J, Wang JB, Lin JX, Chen QY, Cao LL, et al. Prognostic factors for survival after curative resection of gastric mixed adenoneuroendocrine carcinoma: a series of 80 patients. BMC Cancer 2018;18:1021. https://doi.org/10.1186/s12885-018-4943-z
  27. Yang G, Li D, Zheng F, Yang L Long-term disease free survival of gastric mixed adenoneuroendocrine carcinoma treated with multimodality therapy: a case report. Mol Clin Oncol 2018;8:653-656.

Cited by

  1. Serum lipid levels correlate to the progression of gastric cancer with neuroendocrine immunophenotypes: A multicenter retrospective study vol.14, pp.1, 2019, https://doi.org/10.1016/j.tranon.2020.100925